Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: Asasantin ER (new formulation II - high); Drug: Asasantin ER (present commercial formulation); Drug: Asasantin ER (new formulation I - low); Drug: Asasantin ER (new formulation III - medium)

• Registration Number: NCT02273557
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

The objective of this study was to compare the pharmacokinetics of dipyridamole in three different Asasantin ER batches (test) containing different amounts of retarding lacquers to the existing commercial product at steady state with BID treatment

Detailed Description

Not available

Study Timeline

• Study Start: 2003-01
• Primary Completion: 2003-02
• Status Verified: 2014-10
• Study First Submitted: 2014-10-23
• Study First Submitted QC: 2014-10-23
• Last Update Submitted: 2014-10-23
• Study First Posted: 2014-10-24
• Last Update Posted: 2014-10-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 19

Inclusion Criteria

• Healthy male subjects as determined by results of screening
• Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
• Age >=50 years
• BMI >=18.5 and <=29.9 kg/m2
• Able to communicate well with the investigator and to comply with study requirements
• Laboratory values within a clinically defined reference range

Read More

Exclusion Criteria

• Any finding of the medical examination (including blood pressure, pulse rate, and electrocardiogram) deviating from normal and of clinical relevance
• Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic or hormonal disorders
• Surgery of gastrointestinal tract (except appendectomy)
• Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
• History of orthostatic hypotension, fainting spells or blackouts
• Chronic or relevant acute infections
• History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
• Intake of drugs with a long half-life (> 24 hours) (< 1 month prior to administration or during the trial)
• Use of any drugs, which might influence the results of the trial, (< 10 days prior to administration or during the trial)
• Participation in another trial with an investigational drug (< 3 months prior to administration (at least 10 times the relevant elimination half-life) or during trial)
• Having had prescription medication 2 weeks prior to study drug administration or over the counter medication 1 week prior to study drug administration (at least 10 times the relevant elimination half-life)
• Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day)
• Alcohol abuse (> 60 g/day)
• Drug abuse
• Blood donation or loss > 400 mL (< 1 month prior to administration or during the trial)
• Excessive physical activities (< 5 days prior to administration or during the trial)
• Any ECG value outside of the reference range of clinical relevance including, but not limited to QTcB > 480 ms or QRS interval > 110 ms
• History of any familial bleeding disorder
• Inability to comply with dietary regimen of study centre
• Inability to comply with investigator's instructions

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Asasantin ER (new formulation II - high)	Asasantin ER (new formulation II - high)	-
Asasantin ER (present commercial formulation)	Asasantin ER (present commercial formulation)	-
Asasantin ER (new formulation I - low)	Asasantin ER (new formulation I - low)	-
Asasantin ER (new formulation III - medium)	Asasantin ER (new formulation III - medium)	-

Primary Outcome Measures

Name	Time	Method
Urinary excretion of dipyridamole	day 2, day 3	represented by the sum of percentage of amount excreted from time zer0 to 10 h (%Ae 0-10 h), %Ae 10-24h

Secondary Outcome Measures

Name	Time	Method
Number of subjects with adverse events	up to 23 days
Cmin urine (Minimum measured concentration of the analyte)	8- 10 hours after drug intake	Urine collected fraction from 8 - 10 hours as surrogate for Cmin
%PTF urine (Peak trough fluctuation)	Up to 10 hours after drug intake	Estimated from the difference of percentage amount excreted from 1 - 3 hours (%Ae (1-3hours) and %Ae (8-10 hours) divided by the average excretion rate over the total dosing interval
Cmax urine (Maximum measured concentration of the analyte)	0 to 3 hours after drug intake	Urine collected fraction from 0 -3 hours as surrogate for Cmax